ARCHIVES

Genentech Reps Not Welcome: Hospitals Urge Drug Maker to Reverse Policy On Supplying Avastin, Rituxan, & Herceptin

This article is from The Cancer Letter archive.

Vol. 40 No. 39 | October 17, 2014

Download PDF Visit The Full Archive

Related Articles

Report Says Many Cancers Could Be Prevented

February 27, 2009

In Brief: Litton Bionetic’s New contract For Operation of FCRC Total $128.8 Million For Five Years

October 7, 1977

FDA Committee Okays Leuprolide NDA, But Recommends Against Mitoxantrne, Epirubicin

April 5, 1985

CMS Withholds Coverage of CT Colonography

May 15, 2009

FDA Committee Approves NDA for Mitxantrone

March 21, 1986

Patients Sue Milken, Cancer Centers, Over Prostate Cancer Remedy PC-Spes

February 20, 2004